Atea Pharmaceuticals is developing oral direct-acting antiviral therapies, specifically bemnifosbuvir and ruzasvir, for the treatment of hepatitis C virus (HCV) and COVID-19. The company targets the unmet medical need for effective antiviral treatments, as millions of HCV patients remain untreated despite the availability of therapies.
Funding
$215M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFounders
Product
Problem
Millions of individuals with Hepatitis C Virus (HCV) remain untreated despite the availability of existing therapies, highlighting a persistent unmet medical need for effective antiviral treatments. Current treatment regimens may be limited by factors such as tolerability, duration, or pan-genotypic coverage.
Solution
Atea Pharmaceuticals is developing oral direct-acting antiviral therapies, specifically a combination of bemnifosbuvir and ruzasvir, for the treatment of HCV. Both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV as single agents. The combination therapy is currently in Phase 2 clinical trials, with the goal of providing a safe, effective, and short-duration treatment option for HCV patients. Atea leverages its expertise in antiviral drug development to advance novel product candidates targeting single-stranded ribonucleic acid (ssRNA) viruses.
Target Audience
The primary target audience includes individuals infected with Hepatitis C Virus (HCV) and healthcare providers specializing in the treatment of viral diseases.
Features
- Oral direct-acting antiviral agents for convenient administration.
- Bemnifosbuvir: a nucleotide polymerase inhibitor.
- Ruzasvir: an NS5A inhibitor.
- Pan-genotypic antiviral activity, targeting a broad range of HCV genotypes.
- Short treatment duration regimen.
- Phase 2 clinical trial data demonstrating high rates of sustained virologic response (SVR).